{
  "id": "Drug Discovery AI",
  "title": "Drug Discovery AI",
  "content": "- ### OntologyBlock\n  id:: drug-discovery-ai-ontology\n  collapsed:: true\n\t- ontology:: true\n\t- term-id:: AI-0341\n\t- preferred-term:: Drug Discovery AI\n\t- status:: approved\n\t- public-access:: true\n\t- definition:: Drug Discovery AI encompasses artificial intelligence systems that accelerate pharmaceutical research and development through automated molecular design, virtual screening, target identification, toxicity prediction, and clinical trial optimisation. These systems integrate cheminformatics, molecular modelling, and machine learning to reduce drug development timelines and costs whilst improving success rates.\n\t- source:: [[Vamathevan et al. 2025 ACS Omega AI Drug Discovery]], [[FDA 2025 AI for Drug Development]], [[Nature Drug Discovery AI]], [[Barzilay et al. 2025 State of AI Drug Discovery]]\n\t- maturity:: mature\n\t- #### Relationships\n\t  id:: drug-discovery-ai-relationships\n\t  collapsed:: true\n\t\t- is-subclass-of:: [[MedicalAI]]\n\n## Drug Discovery AI\n\nDrug Discovery AI refers to drug discovery ai encompasses artificial intelligence systems that accelerate pharmaceutical research and development through automated molecular design, virtual screening, target identification, toxicity prediction, and clinical trial optimisation. these systems integrate cheminformatics, molecular modelling, and machine learning to reduce drug development timelines and costs whilst improving success rates.\n\n- Industry adoption of Drug Discovery AI is widespread, with platforms increasingly deployed across pharmaceutical companies, biotech firms, and academic institutions.\n  - Notable organisations include NVIDIA, Xaira Therapeutics, Recursion, and Generate: Biomedicines, which leverage generative AI and multimodal data integration to identify novel drug candidates and optimise clinical trials[2].\n  - The US FDA recognises and regulates AI applications throughout the drug product lifecycle, reflecting growing integration in nonclinical, clinical, manufacturing, and postmarketing phases[3].\n- Technical capabilities now encompass:\n  - Generative AI for novel molecular structure creation.\n  - Machine learning models for toxicity and efficacy prediction.\n  - Virtual cell models simulating complex biological interactions.\n  - Natural language processing to mine vast biomedical literature.\n- Limitations remain in data quality, model interpretability, and regulatory acceptance, necessitating rigorous validation and standardisation.\n- Emerging standards and frameworks include FDA guidances on AI use in regulatory decision-making and manufacturing, and industry initiatives for transparency and reproducibility[3][6].\n\n## Technical Details\n\n- **Id**: drug-discovery-ai-ontology\n- **Collapsed**: true\n- **Source Domain**: ai\n- **Status**: draft\n- **Public Access**: true\n\n## Research & Literature\n\n- Key academic sources include:\n  - Vamathevan et al. (2025), \"AI-Driven Drug Discovery: A Comprehensive Review,\" ACS Omega, 10(23), 23889–23903. DOI: 10.1021/acsomega.5c00549 — a critical analysis of AI/ML methodologies across drug discovery phases, emphasising cloud-based implementations and model validation[4].\n  - Barzilay et al. (2025), \"Multimodal AI for Health Care,\" presented at The State of AI in Drug Discovery Summit — highlighting integration of diverse biological data for drug candidate identification[2].\n- Ongoing research focuses on:\n  - Enhancing AI interpretability and explainability.\n  - Integrating real-world data and digital health technologies.\n  - Developing AI models that simulate human biology more accurately.\n  - Addressing ethical and regulatory challenges in AI deployment[1][3][4].\n\n## UK Context\n\n- The UK is a significant contributor to Drug Discovery AI, with strong academic and industrial ecosystems.\n  - Centres of excellence in North England include:\n    - Manchester Institute of Biotechnology, leveraging AI for molecular design and target validation.\n    - Leeds Institute of Biomedical and Clinical Sciences, focusing on AI-driven clinical trial optimisation.\n    - Newcastle University’s Centre for AI and Data Analytics in Health, advancing AI applications in drug safety prediction.\n    - Sheffield’s Advanced Manufacturing Research Centre, integrating AI with automated drug manufacturing processes.\n  - Collaborative initiatives between academia, NHS trusts, and biotech companies foster innovation and translation of AI discoveries into clinical practice.\n- UK government and funding bodies actively support AI in life sciences through programmes like UKRI’s AI for Health and the Medicines Discovery Catapult, with a focus on regional development and commercialisation.\n\n## Future Directions\n\n- Emerging trends include:\n  - Expansion of generative AI capabilities to explore vast chemical spaces with unprecedented creativity.\n  - Integration of AI with digital twins and virtual patients to simulate clinical outcomes more accurately.\n  - Increased use of federated learning to leverage distributed datasets while preserving privacy.\n- Anticipated challenges:\n  - Ensuring data quality, diversity, and representativeness to avoid bias.\n  - Navigating evolving regulatory landscapes and ethical considerations.\n  - Balancing automation with human expertise to maintain scientific rigour.\n- Research priorities focus on:\n  - Developing robust, interpretable AI models.\n  - Enhancing collaboration across disciplines and sectors.\n  - Scaling AI solutions for rare diseases and personalised medicine.\n- One might say the future of Drug Discovery AI is less about replacing scientists and more about giving them a faster, smarter lab assistant—minus the coffee breaks.\n\n## References\n\n1. BiopharmaTrend. (2025). Beyond Legacy Tools: Defining Modern AI Drug Discovery for 2025. BiopharmaTrend.\n2. Barzilay, R., Lowe, D., Lundberg, E., et al. (2025). The State of AI in Drug Discovery 2025. Genetic Engineering & Biotechnology News.\n3. U.S. Food and Drug Administration. (2025). Artificial Intelligence for Drug Development. FDA CDER.\n4. Vamathevan, J., Clark, D., Czodrowski, P., et al. (2025). AI-Driven Drug Discovery: A Comprehensive Review. ACS Omega, 10(23), 23889–23903. https://doi.org/10.1021/acsomega.5c00549\n5. Lifebit. (2025). AI Driven Drug Discovery: 5 Powerful Breakthroughs in 2025. Lifebit Blog.\n6. ELRIG. (2025). Inside ELRIG's Drug Discovery 2025: Automation, AI and Human-Relevant Models. Drug Target Review.\n\n## Metadata\n\n- **Last Updated**: 2025-11-11\n- **Review Status**: Comprehensive editorial review\n- **Verification**: Academic sources verified\n- **Regional Context**: UK/North England where applicable",
  "backlinks": [],
  "wiki_links": [
    "Vamathevan et al. 2025 ACS Omega AI Drug Discovery",
    "Barzilay et al. 2025 State of AI Drug Discovery",
    "FDA 2025 AI for Drug Development",
    "MedicalAI",
    "Nature Drug Discovery AI"
  ],
  "ontology": {
    "term_id": "AI-0341",
    "preferred_term": "Drug Discovery AI",
    "alt_terms": [],
    "iri": null,
    "source_domain": "ai",
    "domain": "ai",
    "domain_full_name": "Artificial Intelligence",
    "definition": "Drug Discovery AI encompasses artificial intelligence systems that accelerate pharmaceutical research and development through automated molecular design, virtual screening, target identification, toxicity prediction, and clinical trial optimisation. These systems integrate cheminformatics, molecular modelling, and machine learning to reduce drug development timelines and costs whilst improving success rates.",
    "scope_note": null,
    "status": "approved",
    "maturity": "mature",
    "version": null,
    "public_access": true,
    "last_updated": null,
    "authority_score": null,
    "quality_score": null,
    "cross_domain_links": null,
    "owl_class": null,
    "owl_physicality": null,
    "owl_role": null,
    "owl_inferred_class": null,
    "is_subclass_of": [
      "MedicalAI"
    ],
    "has_part": [],
    "is_part_of": [],
    "requires": [],
    "depends_on": [],
    "enables": [],
    "relates_to": [],
    "bridges_to": [],
    "bridges_from": [],
    "domain_extensions": {},
    "belongs_to_domain": [],
    "implemented_in_layer": [],
    "source": [
      "Vamathevan et al. 2025 ACS Omega AI Drug Discovery",
      "FDA 2025 AI for Drug Development",
      "Nature Drug Discovery AI",
      "Barzilay et al. 2025 State of AI Drug Discovery"
    ],
    "validation": {
      "is_valid": false,
      "errors": [
        "Missing required property: last-updated",
        "Missing required property: owl:class",
        "Missing required property: owl:physicality",
        "Missing required property: owl:role"
      ]
    }
  }
}